ExoCAR/T7@Micelle crossed the blood-brain barrier, selectively targeted HER2+ breast cancer cells, and enhanced therapeutic efficacy by disrupting ferroptosis defense through drug delivery [93] (Figure 3C). The gene discussed is ERBB2; the disease is breast cancer.